Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling
- DOI
- 10.1186/s12933-021-01312-8
- Published
- 2021-06-11
- Container
- Cardiovascular Diabetology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s12933-021-01312-8,
title = {Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling},
author = {Yuze Zhang and Xiaoyan Lin and Yong Chu and Xiaoming Chen and Heng Du and Hailin Zhang and Changsheng Xu and Hong Xie and Qinyun Ruan and Jinxiu Lin and Jie Liu and Jinzhang Zeng and Ke Ma and Dajun Chai},
year = {2021},
journal = {Cardiovascular Diabetology},
doi = {10.1186/s12933-021-01312-8},
url = {https://doi.org/10.1186/s12933-021-01312-8}
}RIS
TY - JOUR TI - Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling AU - Yuze Zhang AU - Xiaoyan Lin AU - Yong Chu AU - Xiaoming Chen AU - Heng Du AU - Hailin Zhang AU - Changsheng Xu AU - Hong Xie AU - Qinyun Ruan AU - Jinxiu Lin AU - Jie Liu AU - Jinzhang Zeng AU - Ke Ma AU - Dajun Chai PY - 2021 JO - Cardiovascular Diabetology DO - 10.1186/s12933-021-01312-8 UR - https://doi.org/10.1186/s12933-021-01312-8 ER -
APA
Zhang, Y., Lin, X., Chu, Y., Chen, X., Du, H., Zhang, H., Xu, C., Xie, H., Ruan, Q., Lin, J., Liu, J., Zeng, J., Ma, K., & Chai, D. (2021). Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-021-01312-8
Source records
- crossref · retrieved 2026-09-26T13:32:14.679Z